16-16-dimethylprostaglandin-e2 and Liver-Diseases

16,16-Dimethyl PGE2 (dmPGE2) is known to protect against cellular damage in various tissues. Histological and biochemical approaches were used to examine the effect of this prostaglandin on hepatocellular damage in an experimental Reye's syndrome model produced in rats by 4-pentenoic acid. Chronic intraperitoneal administration of 4-pentenoic acid induced an accumulation of fatty droplets throughout the hepatic lobules along with mitochondrial abnormalities including swelling, disappearance of christae, and heterogeneity of matrix. These abnormalities were more intense in the marginal zone and successively decreased nearer to the central vein. Such hepatic abnormalities were markedly reduced by the combined administration of dmPGE2 with 4-pentenoic acid. Biochemical examination confirmed that dmPGE2 was able to inhibit the accumulation of hepatic triglyceride seen after the treatment with 4-pentenoic acid alone. These results indicated that dmPGE2 can prevent characteristic hepatocellular damage in this experimental Reye's syndrome model, suggesting that the involvement of prostaglandins should be taken into account in discussing the etiology and management of this syndrome.

Topics: 16,16-Dimethylprostaglandin E2; Animals; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Fatty Acids, Monounsaturated; Injections, Intraperitoneal; Lipid Metabolism; Lipids; Liver; Liver Diseases; Liver Glycogen; Male; Microscopy, Electron; Rats; Rats, Inbred Strains; Reye Syndrome